Oncogenic role of DDX3 in breast cancer biogenesis

被引:179
|
作者
Botlagunta, M. [1 ]
Vesuna, F. [1 ]
Mironchik, Y. [1 ]
Raman, A. [2 ]
Lisok, A. [1 ]
Winnard, P., Jr. [1 ]
Mukadam, S. [1 ]
Van Diest, P. [3 ]
Chen, J. H. [4 ]
Farabaugh, P.
Patel, A. H. [5 ]
Raman, V. [6 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA
[2] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA
[3] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands
[4] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan
[5] Arvind Patel Inst Virol, Glasgow G11, Lanark, Scotland
[6] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
基金
英国医学研究理事会;
关键词
DDX3; breast cancer; BPDE;
D O I
10.1038/onc.2008.33
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Benzo[a] pyrene diol epoxide (BPDE), the active metabolite of benzo[a] pyrene present in tobacco smoke, is a major cancer-causing compound. To evaluate the effects of BPDE on human breast epithelial cells, we exposed an immortalized human breast cell line, MCF 10A, to BPDE and characterized the gene expression pattern. Of the differential genes expressed, we found consistent activation of DDX3, a member of the DEAD box RNA helicase family. Overexpression of DDX3 in MCF 10A cells induced an epithelial-mesenchymal- like transformation, exhibited increased motility and invasive properties, and formed colonies in soft-agar assays. Besides the altered phenotype, MCF 10A-DDX3 cells repressed E-cadherin expression as demonstrated by both immunoblots and by E-cadherin promoter-reporter assays. In addition, an in vivo association of DDX3 and the E-cadherin promoter was demonstrated by chromatin immunoprecipitation assays. Collectively, these results demonstrate that the activation of DDX3 by BPDE, can promote growth, proliferation and neoplastic transformation of breast epithelial cells.
引用
收藏
页码:3912 / 3922
页数:11
相关论文
共 50 条
  • [21] DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs
    Kukhanova, Marina K.
    Karpenko, Inna L.
    Ivanov, Alexander V.
    MOLECULES, 2020, 25 (04):
  • [22] Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer
    Samal, Sabindra K.
    Routray, Samapika
    Veeramachaneni, Ganesh Kumar
    Dash, Rupesh
    Botlagunta, Mahendran
    SCIENTIFIC REPORTS, 2015, 5
  • [23] The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness
    Wu, Kou-Juey
    BIOMEDICAL JOURNAL, 2020, 43 (02) : 107 - 114
  • [24] Prokaryotic Expression and Affinity Purification of DDX3 Protein
    Huang, Lan
    Liang, Yue
    Hou, Huijin
    Tang, Min
    Liu, Xinpeng
    Ma, Yan-ni
    Liang, Shufang
    PROTEIN AND PEPTIDE LETTERS, 2024, 31 (03): : 236 - 246
  • [25] The translational landscape as regulated by the RNA helicase DDX3
    Park, Joon Tae
    Oh, Sekyung
    BMB REPORTS, 2022, 55 (03) : 125 - 135
  • [26] Diosgenin increased DDX3 expression in hepatocellular carcinoma
    Yu, Hong
    Liu, Yuanni
    Niu, Chuanzhen
    Cheng, Yu
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (11): : 3590 - 3599
  • [27] Rottlerin upregulates DDX3 expression in hepatocellular carcinoma
    Wang, Zhong
    Shen, Gen-hai
    Xie, Jia-ming
    Li, Bin
    Gao, Quan-gen
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (01) : 1503 - 1509
  • [28] Design and synthesis of DDX3 inhibitors as anticancer agent
    Kondaskar, Atul N.
    Kondaskar, Shilpi
    Hosmane, Ramachandra
    Fishbein, James
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [29] Targeting DDX3 in medulloblastoma by RK-33
    Tantravedi, Saritha
    Vesuna, Farhad
    Martin, Allison
    Lim, Michael
    Eberhart, Charles G. Eberhart G.
    van Diest, Paul J.
    Raman, Venu
    CANCER RESEARCH, 2018, 78 (13)
  • [30] A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression
    He, Yu
    Zhang, Dan
    Yang, Yanfang
    Wang, Xixi
    Zhao, Xinyu
    Zhang, Peng
    Zhu, Hongxia
    Xu, Ningzhi
    Liang, Shufang
    ONCOLOGY REPORTS, 2018, 39 (03) : 883 - 892